Acquired von Willebrand disease: correction of hemostatic defect by high-dose intravenous immunoglobulins.
High-dose intravenous immunoglobulins (ivIG) were used in a 57-year-old patient with acquired von Willebrand disease in order to correct a hemostatic defect before pneumonectomy for lung carcinoma. IvIG induced a rapid and complete correction of factor VIII (F VIII) and von Willebrand factor (vWF) and allowed surgery without additional factor coverage. F VIII and vWF returned to baseline values within 10 days after ivIG.
Delmer
A
A
Service d'Hématologie, Hôtel-Dieu, Paris, France.
Horellou
M H
MH
Bréchot
J M
JM
Prudent
J
J
Potevin
F
F
Lecrubier
C
C
Girard-Longhini
C
C
Samama
M
M
Zittoun
R
R
D004305:Dose-Response Relationship, Drug; D005169:Factor VIII / Q000032:analysis; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014842:von Willebrand Diseases / Q000097:blood / Q000188:drug therapy*; D014841:von Willebrand Factor / Q000032:analysis
D016756:Immunoglobulins, Intravenous; D014841:von Willebrand Factor; D005169:Factor VIII